3960 studies found for:    Japan
Show Display Options
Rank Status Study
1 Recruiting Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Condition: Castration-resistant Prostate Cancer
Intervention: Drug: Xtandi
2 Active, not recruiting Zenith® TXD Post-market Surveillance in Japan
Condition: Aortic Dissection
Intervention: Device: Zenith® TXD
3 Recruiting An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
Condition: Palmoplantar Pustulosis
Interventions: Drug: Guselkumab;   Drug: Placebo
4 Recruiting A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Condition: Migraine
Interventions: Drug: AMG 334 Dose Level 1;   Drug: Placebo;   Drug: AMG 334 Dose Level 2;   Drug: AMG 334 Dose Level 3
5 Not yet recruiting Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: olodaterol
6 Recruiting Special Drug Use Surveillance of Irribow in Female Patients
Condition: Diarrhea-predominant Irritable Bowel Syndrome
Intervention: Drug: Ramosetron
7 Recruiting All-Case Surveillance of Ofev in Patients With IPF in Japan
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: Nintedanib
8 Recruiting Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo
9 Recruiting The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Mellitus (T1DM)
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Dapagliflozin 5 mg;   Drug: Dapagliflozin 10mg
10 Recruiting A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma
Condition: I.V Advanced Cancer
Interventions: Drug: Nivolumab;   Drug: Sorafenib
11 Completed Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
Conditions: Overactive Bladder;   Cardiovascular Disease
Intervention: Drug: Mirabegron
12 Recruiting Study of ONO-4538 in Unresectable Advanced or Recurrent Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: ONO-4538;   Drug: Docetaxel/Paclitaxel
13 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
14 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
15 Recruiting A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions: Metastatic Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions: Drug: Ramucirumab;   Drug: Placebo;   Drug: S-1;   Drug: Oxaliplatin;   Drug: Paclitaxel
16 Recruiting A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy
Condition: Lung Cancer
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Other: Placebo
17 Recruiting Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF;   Drug: COPE
18 Active, not recruiting XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS)
Conditions: Ischemic Heart Disease;   Angina Pectoris;   Coronary Artery Disease;   Coronary Artery Occlusion;   Myocardial Ischemia
Intervention: Device: XIENCE PRIME SV Everolimus Eluting Coronary Stent
19 Recruiting A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
20 Recruiting Effects of Abatacept in Patients With Early Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Methotrexate;   Other: Abatacept Placebo;   Other: Methotrexate Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years